Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data

Active, not recruitingOBSERVATIONAL

Enrollment

11,265

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Diabetes Mellitus, Type 2Heart Failure With Preserved Ejection Fraction (HFPEF)

Interventions

DRUG

Tirzepatide

New use of tirzepatide dispensing claim is used as the exposure.

DRUG

Placebo

New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT06914154 - Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter